Sanara MedTech Inc. will announce Q1 2025 financial results on May 14, hosting a conference call for discussion.
Quiver AI Summary
Sanara MedTech Inc. announced that it will report its first quarter 2025 financial results on May 14, 2025, before U.S. markets open. A conference call will take place that same day at 8:00 a.m. Eastern Time to discuss the financial results for the quarter ending March 31, 2025, including a Q&A session. Sanara, a medical technology company specializing in transformative healthcare technologies for surgical, wound, and skincare markets, focuses on improving clinical outcomes while reducing healthcare costs. The company markets various advanced biologic products and is committed to developing new technologies and forming strategic partnerships in the healthcare sector. A replay of the conference call will be available for a limited time afterward.
Potential Positives
- Sanara MedTech Inc. is scheduled to report its first-quarter 2025 financial results, providing an opportunity for investors and stakeholders to assess the company's performance.
- The company will host a conference call and webcast to discuss the financial results, allowing for direct engagement and Q&A with investors.
- Sanara continues to focus on transformative technologies in the surgical and wound care markets, highlighting its commitment to improving clinical outcomes and reducing healthcare expenditures.
- The announcement emphasizes Sanara's diverse product portfolio, which includes advanced biologic products aimed at addressing significant healthcare challenges.
Potential Negatives
- None
FAQ
When will Sanara MedTech report its first quarter 2025 financial results?
Sanara MedTech will report its first quarter 2025 financial results on May 14, 2025.
What time is the conference call for the financial results?
The conference call will take place at 8:00 a.m. Eastern Time on May 14, 2025.
How can I listen to the conference call?
You can listen to the conference call by dialing 888-506-0062 or through a live webcast on the investor relations website.
Is there a replay available for the conference call?
Yes, a telephonic replay will be available until May 28, 2025, by dialing 877-481-4010.
What products does Sanara MedTech develop and market?
Sanara MedTech develops and markets surgical, wound, and skincare products, including CellerateRX® and BIAKŌS® product lines.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SMTI Hedge Fund Activity
We have seen 31 institutional investors add shares of $SMTI stock to their portfolio, and 6 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MARSHALL WACE, LLP added 30,285 shares (+inf%) to their portfolio in Q4 2024, for an estimated $1,005,462
- VANGUARD GROUP INC added 27,780 shares (+16.1%) to their portfolio in Q4 2024, for an estimated $922,296
- FIFTH THIRD BANCORP removed 27,037 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $834,632
- RENAISSANCE TECHNOLOGIES LLC added 21,400 shares (+152.9%) to their portfolio in Q4 2024, for an estimated $710,480
- GOLDMAN SACHS GROUP INC added 12,332 shares (+inf%) to their portfolio in Q4 2024, for an estimated $409,422
- JPMORGAN CHASE & CO added 9,516 shares (+234.5%) to their portfolio in Q4 2024, for an estimated $315,931
- DIMENSIONAL FUND ADVISORS LP added 8,567 shares (+116.4%) to their portfolio in Q4 2024, for an estimated $284,424
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
FORT WORTH, TX, April 23, 2025 (GLOBE NEWSWIRE) --
Sanara MedTech Inc
.
(“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today announced it will report its first quarter 2025 financial results on Wednesday, May 14, 2025 before the U.S. financial markets open.
The Company will host a conference call and webcast on May 14, 2025 at 8:00 a.m. Eastern Time to discuss the results of the quarter ended March 31, 2025 and hold a question and answer session at the end of the call. The toll-free number to call for this teleconference is 888-506-0062 (international callers: 973-528-0011) and the access code is 490762. A telephonic replay of the conference call will be available through Wednesday, May 28, 2025, by dialing 877-481-4010 (international callers: 919-882-2331) and entering the replay passcode: 52308.
A live webcast of Sanara’s conference call is accessible by clicking
here
and will be made available under the ‘Events’ section of the Company's Investor Relations website,
www.SanaraMedTech.com/investor-relations/
. An online replay will be available for approximately one year following the conclusion of the live broadcast.
About Sanara MedTech Inc.
Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. The Company markets, distributes and develops surgical, wound and skincare products for use by physicians and clinicians in hospitals, clinics and all post-acute care settings. Sanara’s products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara markets and distributes CellerateRX
®
Surgical Activated Collagen, FORTIFY TRG
®
Tissue Repair Graft and FORTIFY FLOWABLE
®
Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN
TM
Verified Inductive Bone Matrix, ALLOCYTE
®
Plus Advanced Viable Bone Matrix, BiFORM
®
Bioactive Moldable Matrix, TEXAGEN
®
Amniotic Membrane Allograft, and BIASURGE
®
Advanced Surgical Solution to the surgical market. In addition, the following products are sold in the wound care market: BIAKŌS
®
Antimicrobial Skin and Wound Cleanser, BIAKŌS
®
Antimicrobial Wound Gel, and BIAKŌS
®
Antimicrobial Skin and Wound Irrigation Solution. Sanara’s pipeline also contains potentially transformative product candidates for mitigation of opportunistic pathogens and biofilm, wound re-epithelialization and closure, necrotic tissue debridement and cell compatible substrates. The Company believes it has the ability to drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. Sanara is constantly seeking long-term strategic partnerships with a focus on products that improve outcomes at a lower overall cost. For more information, please visit sanaramedtech.com.
Information about Forward-Looking Statements
The statements in this press release that do not constitute historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified by terms such as “aims,” “anticipates,” “believes,” “contemplates,” “continue,” “could,” “estimates,” “expects,” “forecast,” “guidance,” “intends,” “may,” “plans,” “possible,” “potential,” “predicts,” “preliminary,” “projects,” “seeks,” “should,” “targets,” “will,” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include, among others, statements regarding the Company’s business strategy and mission, the development of new products, the timing of commercialization of products, the regulatory approval process and expansion of the Company’s business in value-based wound care. These items involve risks, contingencies and uncertainties such as uncertainties associated with the development and process for obtaining regulatory approval for new products, the Company’s ability to build out its executive team, the Company’s ability to identify and effectively utilize the net proceeds of its term loan to support the Company’s growth initiatives, the extent of product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, uncertainties associated with the development and process for obtaining regulatory approval for new products, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s filings with the Securities and Exchange Commission, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements.
All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect future circumstances or the occurrence of unanticipated events, except as required by applicable securities laws.
Investor Relations Contact:
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
